Literature DB >> 31871109

Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon.

Babatunde Adedokun1, Yonglan Zheng1, Paul Ndom2, Antony Gakwaya3, Timothy Makumbi4, Alicia Y Zhou5, Toshio F Yoshimatsu1, Alex Rodriguez6, Ravi K Madduri6,7, Ian T Foster6,7, Aminah Sallam1,8, Olufunmilayo I Olopade9, Dezheng Huo9,10.   

Abstract

BACKGROUND: Sub-Saharan Africa (SSA) has a high proportion of premenopausal hormone receptor negative breast cancer. Previous studies reported a strikingly high prevalence of germline mutations in BRCA1 and BRCA2 among Nigerian patients with breast cancer. It is unknown if this exists in other SSA countries.
METHODS: Breast cancer cases, unselected for age at diagnosis and family history, were recruited from tertiary hospitals in Kampala, Uganda and Yaoundé, Cameroon. Controls were women without breast cancer recruited from the same hospitals and age-matched to cases. A multigene sequencing panel was used to test for germline mutations.
RESULTS: There were 196 cases and 185 controls with a mean age of 46.2 and 46.6 years for cases and controls, respectively. Among cases, 15.8% carried a pathogenic or likely pathogenic mutation in a breast cancer susceptibility gene: 5.6% in BRCA1, 5.6% in BRCA2, 1.5% in ATM, 1% in PALB2, 0.5% in BARD1, 0.5% in CDH1, and 0.5% in TP53. Among controls, 1.6% carried a mutation in one of these genes. Cases were 11-fold more likely to carry a mutation compared with controls (OR = 11.34; 95% confidence interval, 3.44-59.06; P < 0.001). The mean age of cases with BRCA1 mutations was 38.3 years compared with 46.7 years among other cases without such mutations (P = 0.03).
CONCLUSIONS: Our findings replicate the earlier report of a high proportion of mutations in BRCA1/2 among patients with symptomatic breast cancer in SSA. IMPACT: Given the high burden of inherited breast cancer in SSA countries, genetic risk assessment could be integrated into national cancer control plans. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31871109      PMCID: PMC7007381          DOI: 10.1158/1055-9965.EPI-19-0506

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  52 in total

1.  Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.

Authors:  S A Vaziri; L M Krumroy; M Rostai; G Casey
Journal:  Hum Mutat       Date:  2001       Impact factor: 4.878

2.  The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data.

Authors:  A Y Bahar; P J Taylor; L Andrews; A Proos; L Burnett; K Tucker; M Friedlander; M F Buckley
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 3.  BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.

Authors:  Allison W Kurian
Journal:  Curr Opin Obstet Gynecol       Date:  2010-02       Impact factor: 1.927

4.  BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.

Authors:  Helen A Shih; Fergus J Couch; Katherine L Nathanson; M Anne Blackwood; Timothy R Rebbeck; Katrina A Armstrong; Kathleen Calzone; Jill Stopfer; Sheila Seal; Michael R Stratton; Barbara L Weber
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

Authors:  A M Martin; M A Blackwood; D Antin-Ozerkis; H A Shih; K Calzone; T A Colligon; S Seal; N Collins; M R Stratton; B L Weber; K L Nathanson
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

6.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

7.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

Authors:  Jeffrey N Weitzel; Jessica Clague; Arelis Martir-Negron; Raquel Ogaz; Josef Herzog; Charité Ricker; Chelsy Jungbluth; Cheryl Cina; Paul Duncan; Gary Unzeitig; J Salvador Saldivar; Mary Beattie; Nancy Feldman; Sharon Sand; Danielle Port; Deborah I Barragan; Esther M John; Susan L Neuhausen; Garrett P Larson
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

8.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

Authors:  Fergus J Couch; Steven N Hart; Priyanka Sharma; Amanda Ewart Toland; Xianshu Wang; Penelope Miron; Janet E Olson; Andrew K Godwin; V Shane Pankratz; Curtis Olswold; Seth Slettedahl; Emily Hallberg; Lucia Guidugli; Jaime I Davila; Matthias W Beckmann; Wolfgang Janni; Brigitte Rack; Arif B Ekici; Dennis J Slamon; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; George Fountzilas; Liisa M Pelttari; William J Tapper; Lorraine Durcan; Simon S Cross; Robert Pilarski; Charles L Shapiro; Jennifer Klemp; Song Yao; Judy Garber; Angela Cox; Hiltrud Brauch; Christine Ambrosone; Heli Nevanlinna; Drakoulis Yannoukakos; Susan L Slager; Celine M Vachon; Diana M Eccles; Peter A Fasching
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

9.  The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.

Authors:  C Villarreal-Garza; J N Weitzel; M Llacuachaqui; E Sifuentes; M C Magallanes-Hoyos; L Gallardo; R M Alvarez-Gómez; J Herzog; D Castillo; R Royer; Mohammad Akbari; F Lara-Medina; L A Herrera; A Mohar; S A Narod
Journal:  Breast Cancer Res Treat       Date:  2015-02-26       Impact factor: 4.872

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  16 in total

1.  Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.

Authors:  Sonya Reid; Sydney Cadiz; Tuya Pal
Journal:  Curr Breast Cancer Rep       Date:  2020-05-19

Review 2.  Cancer Risk Studies and Priority Areas for Cancer Risk Appraisal in Uganda.

Authors:  Alfred Jatho; Binh Thang Tran; Jansen Marcos Cambia; Miisa Nanyingi; Noleb Mugume Mugisha
Journal:  Ann Glob Health       Date:  2020-07-07       Impact factor: 2.462

Review 3.  Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.

Authors:  Wejdan M Alenezi; Caitlin T Fierheller; Neil Recio; Patricia N Tonin
Journal:  Genes (Basel)       Date:  2020-07-27       Impact factor: 4.096

4.  BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort.

Authors:  Paula Rofes; Jesús Del Valle; Sara Torres-Esquius; Lídia Feliubadaló; Agostina Stradella; José Marcos Moreno-Cabrera; Adriana López-Doriga; Elisabet Munté; Rafael De Cid; Olga Campos; Raquel Cuesta; Álex Teulé; Èlia Grau; Judit Sanz; Gabriel Capellá; Orland Díez; Joan Brunet; Judith Balmaña; Conxi Lázaro
Journal:  Genes (Basel)       Date:  2021-01-23       Impact factor: 4.096

5.  Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.

Authors:  Sophia H L George; Talia Donenberg; Cheryl Alexis; Vincent DeGennaro; Hedda Dyer; Sook Yin; Jameel Ali; Raleigh Butler; Sheray N Chin; DuVaughn Curling; Dwight Lowe; John Lunn; Theodore Turnquest; Gilian Wharfe; Danielle Cerbon; Priscila Barreto-Coelho; Matthew P Schlumbrecht; Mohammad R Akbari; Steven A Narod; Judith E Hurley
Journal:  JAMA Netw Open       Date:  2021-03-01

6.  Germline sequence variants contributing to cancer susceptibility in South African breast cancer patients of African ancestry.

Authors:  Elizabeth J van Rensburg; Fourie Joubert; Dewald Eygelaar
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

7.  Feasibility of genetic testing for cancer risk assessment programme in Nigeria.

Authors:  Prisca O Adejumo; Toyin I G Aniagwu; Olutosin A Awolude; Abiodun O Oni; Olubunmi O Ajayi; Omolara Fagbenle; Dasola Ogungbade; Makayla Kochheiser; Temidayo Ogundiran; Olufunmilayo I Olopade
Journal:  Ecancermedicalscience       Date:  2021-09-07

8.  Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study.

Authors:  Kristen S Purrington; Sreejata Raychaudhuri; Michael S Simon; Julie Clark; Valerie Ratliff; Gregory Dyson; Douglas B Craig; Julie L Boerner; Jennifer L Beebe-Dimmer; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-31       Impact factor: 4.254

9.  Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.

Authors:  Malwina Suszynska; Piotr Kozlowski
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

10.  Breast cancer awareness and screening practice amongst health personnel and general population of the littoral region of Cameroon.

Authors:  Mohamadou Halmata; Richard Simo Tagne; Grace Nganwa Kembaou; Erika Myriam Baiguerel; Lydiane C C Ndopwang; Armel Herve Nwabo Kamdje; Phelix Bruno Telefo; Charlette Nangue; Elias Nchiwan Nukenine
Journal:  Heliyon       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.